SLC5A2 and hydrops fetalis: It was shown in a recent meta-analysis of the EMPA-RESPONSE-AHF, SOLOIST-WHF, and EMPULSE trial that the early initiation of SGLT2 inhibitors reduces the risk of rehospitalization for HF and improves patient-reported outcomes with no excess risk of adverse effects [20].